Mealey's (May 17, 2021, 2:16 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on May 17 denied a petition by Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. to review Pennsylvania state court rulings that drug maker defendants failed to warn plaintiffs that the off-label use of the atypical antipsychotic drug Risperdal caused enlarged breasts in a young male, including one ruling that resulted in a $70 million verdict that is awaiting a punitive damages proceeding....